Literature DB >> 25064493

Indoleamine 2,3-dioxygenase increases p53 levels in alloreactive human T cells, and both indoleamine 2,3-dioxygenase and p53 suppress glucose uptake, glycolysis and proliferation.

Theodoros Eleftheriadis1, Georgios Pissas2, Georgia Antoniadi2, Aginor Spanoulis2, Vassilios Liakopoulos2, Ioannis Stefanidis2.   

Abstract

Indoleamine 2,3-dioxygenase (IDO) suppresses adaptive immunity by inhibiting T-cell proliferation and altering glucose metabolism. The tumor suppressor p53 also alters these cellular processes with similar results. The effect of IDO on p53 and on glucose metabolism was evaluated in alloreactive T cells. Mixed-lymphocyte reactions (MLRs) were performed in the presence or not of the IDO inhibitor, 1-dl-methyl-tryptophan (1-MT) and/or the p53 inhibitor, pifithrin-α (PFT). Cell proliferation, glucose consumption and lactate production were assessed. 1-MT increased cell proliferation, glucose influx and lactate production, whereas PFT enhanced cell proliferation and glucose influx, leaving lactate production unaffected. In MLR-derived T cells, protein analysis revealed that IDO activated general control non-derepressible 2 kinase and induced p53, p-p53 (p53 phosphorylated at serine 15) and p21. In addition, both IDO and p53 decreased glucose transporter 1 and TP53-induced glycolysis and apoptosis regulator and increased synthesis of cytochrome c oxidase 2. IDO also reduced lactate dehydrogenase-A and glutaminase 2 levels, whereas p53 left them unaffected. Neither 1-MT nor PFT affected glucose-6-phosphate dehydrogenase. In conclusion, in alloreactive T cells, IDO increases p53 levels, and both IDO and p53 inhibit cell proliferation, glucose consumption and glycolysis. Lactate production and glutaminolysis are also suppressed by IDO, but not by p53. © The Japanese Society for Immunology. 2014. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  3-dioxygenase; GCN2 kinase; T cells; aerobic glycolysis; glutaminolysis; indoleamine 2; p53; proliferation

Mesh:

Substances:

Year:  2014        PMID: 25064493     DOI: 10.1093/intimm/dxu077

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  19 in total

1.  In human cell cultures, everolimus is inferior to tacrolimus in inhibiting cellular alloimmunity, but equally effective as regards humoral alloimmunity.

Authors:  Theodoros Eleftheriadis; Georgios Pissas; Maria Sounidaki; Georgia Antoniadi; Nikolaos Antoniadis; Vassilios Liakopoulos; Ioannis Stefanidis
Journal:  Int Urol Nephrol       Date:  2017-05-15       Impact factor: 2.370

2.  Indoleamine 2,3-dioxygenase depletes tryptophan, activates general control non-derepressible 2 kinase and down-regulates key enzymes involved in fatty acid synthesis in primary human CD4+ T cells.

Authors:  Theodoros Eleftheriadis; Georgios Pissas; Georgia Antoniadi; Vassilios Liakopoulos; Ioannis Stefanidis
Journal:  Immunology       Date:  2015-07-27       Impact factor: 7.397

3.  Angiogenin is upregulated during the alloreactive immune response and has no effect on the T-cell expansion phase, whereas it affects the contraction phase by inhibiting CD4+ T-cell apoptosis.

Authors:  Theodoros Eleftheriadis; Georgios Pissas; Maria Sounidaki; Nikolaos Antoniadis; Georgia Antoniadi; Vassilios Liakopoulos; Ioannis Stefanidis
Journal:  Exp Ther Med       Date:  2016-10-06       Impact factor: 2.447

4.  Tryptophan depletion under conditions that imitate insulin resistance enhances fatty acid oxidation and induces endothelial dysfunction through reactive oxygen species-dependent and independent pathways.

Authors:  Theodoros Eleftheriadis; Georgios Pissas; Maria Sounidaki; Georgia Antoniadi; Christos Rountas; Vassilios Liakopoulos; Loannis Stefanidis
Journal:  Mol Cell Biochem       Date:  2017-02-04       Impact factor: 3.396

5.  Preconditioning of primary human renal proximal tubular epithelial cells without tryptophan increases survival under hypoxia by inducing autophagy.

Authors:  Theodoros Eleftheriadis; Georgios Pissas; Maria Sounidaki; Nikolaos Antoniadis; Georgia Antoniadi; Vassilios Liakopoulos; Ioannis Stefanidis
Journal:  Int Urol Nephrol       Date:  2017-04-17       Impact factor: 2.370

6.  LW106, a novel indoleamine 2,3-dioxygenase 1 inhibitor, suppresses tumour progression by limiting stroma-immune crosstalk and cancer stem cell enrichment in tumour micro-environment.

Authors:  Rong Fu; Yi-Wei Zhang; Hong-Mei Li; Wen-Cong Lv; Li Zhao; Qing-Long Guo; Tao Lu; Stephen J Weiss; Zhi-Yu Li; Zhao-Qiu Wu
Journal:  Br J Pharmacol       Date:  2018-06-03       Impact factor: 8.739

7.  Activation of general control nonderepressible 2 kinase protects human glomerular endothelial cells from harmful high-glucose-induced molecular pathways.

Authors:  Theodoros Eleftheriadis; Konstantina Tsogka; Georgios Pissas; Georgia Antoniadi; Vassilios Liakopoulos; Ioannis Stefanidis
Journal:  Int Urol Nephrol       Date:  2016-07-27       Impact factor: 2.370

8.  Malate dehydrogenase-2 inhibitor LW6 promotes metabolic adaptations and reduces proliferation and apoptosis in activated human T-cells.

Authors:  Theodoros Eleftheriadis; Georgios Pissas; Georgia Antoniadi; Vassilios Liakopoulos; Ioannis Stefanidis
Journal:  Exp Ther Med       Date:  2015-09-22       Impact factor: 2.447

Review 9.  Tryptophan-kynurenine pathway is dysregulated in inflammation, and immune activation.

Authors:  Qiongxin Wang; Danxia Liu; Ping Song; Ming-Hui Zou
Journal:  Front Biosci (Landmark Ed)       Date:  2015-06-01

10.  Metabonomics applied in exploring the antitumour mechanism of physapubenolide on hepatocellular carcinoma cells by targeting glycolysis through the Akt-p53 pathway.

Authors:  Ting Ma; Bo-Yi Fan; Chao Zhang; Hui-Jun Zhao; Chao Han; Cai-Yun Gao; Jian-Guang Luo; Ling-Yi Kong
Journal:  Sci Rep       Date:  2016-07-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.